EPO mRNA encodes human erythropoietin (EPO), a 30.4 kDa glycoprotein hormone containing four N-linked glycosylation sites. While EPO is synthesized primarily in the kidneys under hypoxic conditions, fetal production occurs in the fetal liver with hepatic expression persisting into adulthood. This hormone critically regulates erythropoiesis by binding to erythropoietin receptors (EPOR) on erythroid progenitor cells, activating JAK2/STAT5 signaling pathways that promote cellular proliferation, differentiation, and survival. Clinically, EPO mRNA is widely utilized in protein replacement therapies, particularly for treating anemia associated with chronic kidney disease where endogenous EPO production is deficient.

• Experimental studies and validation of the regulatory functions of human EPO in various biological processes.

• Sequence optimized and selected for high expression.

• Oligo-dT purification ensures high quality and purity.

• Carefully controlled processes to minimize batch-to-batch variation.